Home > > > > Report Detail

Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 80
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Chemotherapy Induced Nausea and Vomiting Understanding

Chemotherapy Induced Nausea and Vomiting: Overview

Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.

"Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.

Chemotherapy Induced Nausea and Vomiting Emerging Drugs Chapters

This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chemotherapy Induced Nausea and Vomiting Emerging Drugs

- APD403: Acacia Pharma

APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. The drug is currently in Phase II clinical studies for Chemotherapy-induced nausea and vomiting.

- CAM2047: Camurus

CAM2047 is along-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. It is currently under Phase I stage of development for the treatment of Chemotherapy-induced nausea and vomiting.

Further product details are provided in the report……..

Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Chemotherapy Induced Nausea and Vomiting

There are approx. 15+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase II include, Acacia Pharma.

- Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravitreal

- Subretinal

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.

Chemotherapy Induced Nausea and Vomiting Report Insights

- Chemotherapy Induced Nausea and Vomiting Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Chemotherapy Induced Nausea and Vomiting Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?

- How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Acacia Pharma

- Camurus

- LP Pharmaceuticals

- Skye Bioscience

- TALLC Corporation

- Starton Therapeutics

Key Products

- APD403

- CAM2047

- Palonosetron buccal

- Research program: cannabis-based therapeutics

- TA-A002

- Ondansetron transdermal

Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Chemotherapy Induced Nausea and Vomiting: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Chemotherapy Induced Nausea and Vomiting - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Chemotherapy Induced Nausea and Vomiting companies' collaborations, Licensing, Acquisition -Deal Value Trends
Chemotherapy Induced Nausea and Vomiting Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
APD403: Acacia Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CAM2047: Camurus
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
TA-A002: TALLC Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Chemotherapy Induced Nausea and Vomiting Key Companies
Chemotherapy Induced Nausea and Vomiting Key Products
Chemotherapy Induced Nausea and Vomiting- Unmet Needs
Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
Chemotherapy Induced Nausea and Vomiting Analyst Views
Chemotherapy Induced Nausea and Vomiting Key Companies
Appendix

List of Tables

Table 1 Total Products for Chemotherapy Induced Nausea and Vomiting
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Chemotherapy Induced Nausea and Vomiting
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Thyroid Gland Disorders Treatment Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Thyroid Gland Disorder Treatment is a kind of treatment method, which aims to The thyroid disorder patients, such as hypothyroidism patients and hyperthyroidism patients. When The thyroid gland does not produce sufficient hypothyroidism or too much hyperthyroidism, The body metabolism and functioning will be disrupted. The global Thyroid Gland Disorders Treatment market was valued at US$ 2950 million in 2023 and is anticipated to reach US$ 3871.9 million by 2030, witnessing a CAGR o......
  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 98
    According to our LPI (LP Information) latest study, the global Brachytherapy Afterloaders, Brachytherapy Seeds market size was valued at US$ 150.8 million in 2023. With growing demand in downstream market, the Brachytherapy Afterloaders, Brachytherapy Seeds is forecast to a readjusted size of US$ 168.1 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Brachytherapy Afterloaders, Brachytherapy Seeds market. Brachyth......
  • Global Peptide Therapeutics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 109
    According to our LPI (LP Information) latest study, the global Peptide Therapeutics market size was valued at US$ 33800 million in 2023. With growing demand in downstream market, the Peptide Therapeutics is forecast to a readjusted size of US$ 63130 million by 2030 with a CAGR of 9.3% during review period. The research report highlights the growth potential of the global Peptide Therapeutics market. Peptide Therapeutics are expected to show stable growth in the future market. However, pr......
  • Global Microbiome Therapeutics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 155
    According to our LPI (LP Information) latest study, the global Microbiome Therapeutics market size was valued at US$ 89 million in 2023. With growing demand in downstream market, the Microbiome Therapeutics is forecast to a readjusted size of US$ 916.3 million by 2030 with a CAGR of 39.5% during review period. The research report highlights the growth potential of the global Microbiome Therapeutics market. Microbiome Therapeutics are expected to show stable growth in the future market. H......
  • Global Anti-inflammatory Therapeutics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 109
    According to our LPI (LP Information) latest study, the global Anti-inflammatory Therapeutics market size was valued at US$ 108140 million in 2023. With growing demand in downstream market, the Anti-inflammatory Therapeutics is forecast to a readjusted size of US$ 166150 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Anti-inflammatory Therapeutics market. Anti-inflammatory Therapeutics are expected to show stabl......
  • Global Enzyme Replacement Therapy Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 113
    According to our LPI (LP Information) latest study, the global Enzyme Replacement Therapy market size was valued at US$ 11570 million in 2023. With growing demand in downstream market, the Enzyme Replacement Therapy is forecast to a readjusted size of US$ 29900 million by 2030 with a CAGR of 14.5% during review period. The research report highlights the growth potential of the global Enzyme Replacement Therapy market. Enzyme Replacement Therapy are expected to show stable growth in the f......
  • Global Infantile Spasms Therapeutics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 84
    According to our LPI (LP Information) latest study, the global Infantile Spasms Therapeutics market size was valued at US$ 138.9 million in 2023. With growing demand in downstream market, the Infantile Spasms Therapeutics is forecast to a readjusted size of US$ 179.6 million by 2030 with a CAGR of 3.7% during review period. The research report highlights the growth potential of the global Infantile Spasms Therapeutics market. Infantile Spasms Therapeutics are expected to show stable grow......
  • Global Hormone Replacement Therapy Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 128
    According to our LPI (LP Information) latest study, the global Hormone Replacement Therapy market size was valued at US$ 16090 million in 2023. With growing demand in downstream market, the Hormone Replacement Therapy is forecast to a readjusted size of US$ 17930 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Hormone Replacement Therapy market. Hormone Replacement Therapy are expected to show stable growth in th......
  • Global Plasma Therapy Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 107
    According to our LPI (LP Information) latest study, the global Plasma Therapy market size was valued at US$ 265.3 million in 2023. With growing demand in downstream market, the Plasma Therapy is forecast to a readjusted size of US$ 529.4 million by 2030 with a CAGR of 10.4% during review period. The research report highlights the growth potential of the global Plasma Therapy market. Plasma Therapy are expected to show stable growth in the future market. However, product differentiation, ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs